Repeated ischaemic preconditioning: A novel therapeutic intervention and potential underlying mechanisms. by Thijssen, DHJ et al.
Thijssen et al. Invited Review Experimental Physiology 
Repeated ischaemic preconditioning:  
A novel therapeutic intervention and potential underlying 
mechanisms 
 
DICK H.J. THIJSSEN
1,2
 
JOSEPH MAXWELL
1 
DANIEL J. GREEN
1,3
 
N. TIMOTHY CABLE
1,3,4
 
HELEN JONES
1
 
 
1
Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, 
United Kingdom 
2
Radboud Institute for Health Sciences, Department of Physiology, Radboud University 
Medical Center, the Netherlands 
3
School of Sports Science, Exercise and Health, The University of Western Australia 
4
Department of Sport Science, Aspire Academy, Qatar 
 
WORD COUNT: 6,121 
ABSTRACT WORD COUNT: 194 
FIGURES: 4 
TABLES: 1 
 
Author for correspondence: 
Prof. Dick Thijssen, Research Institute of Sport and Exercise Sciences, Liverpool John 
Moores University, Tom Reilly Building, L3 3AF, Liverpool, United Kingdom.  
Email: d.thijssen@ljmu.ac.uk, Tel: +44 151 904 62 64 
Thijssen et al. Invited Review Experimental Physiology 
NEW FINDINGS 
What is the topic of this review? 
This review discusses the effects of repeatedly exposing tissue to ischaemic preconditioning 
on cardiovascular function, the attendant adaptations and their potential clinical relevance. 
 
What advances does it highlight? 
We discuss the effects of episodic exposure to IPC to prevent and/or attenuate ischaemic 
injury, and summarise evidence pertaining to improvements in cardiovascular function and 
structure. Discussion is provided regarding the potential mechanisms that contribute to both 
local and systemic adaptation. Findings suggest that clinical benefits result from both the 
prevention of ischaemic events and attenuation of their consequences. 
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ABSTRACT 
Ischaemic preconditioning (IPC) refers to the phenomenon that short periods of cyclical 
tissue ischaemia confer subsequent protection against ischaemia-induced injury. As a 
consequence, IPC can ameliorate the myocardial damage following infarction and reduce 
infarct size. The ability of IPC to confer remote protection makes IPC a potentially feasible 
cardioprotective strategy. In this review, we discuss the concept that repeatedly exposing 
tissue to IPC may increase the “dose” of protection, and subsequently lead to enhanced 
protection against ischaemia-induced myocardial injury. This may be relevant for clinical 
populations, who demonstrate attenuated efficacy of IPC to prevent or attenuate ischaemic 
injury (and therefore myocardial infarct size). Furthermore, episodic IPC facilitates repeated 
exposure to local (e.g. shear stress) and systemic (e.g. hormones, cytokines, blood-borne 
substances) stimuli, which may induce improvement in vascular function and health. Such 
adaptation may contribute to prevention of cardio- and cerebro-vascular events. The clinical 
benefits of repeated IPC may, therefore, result from both the prevention of ischaemic events 
and attenuation of their consequences. We provide an overview of the literature pertaining to 
the impact of repeated IPC on cardiovascular function, related to both local and or remote 
adaptation, as well as potential clinical implications. 
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Ischaemic preconditioning (IPC) refers to the phenomenon whereby 3-4 brief periods of 
ischaemia, followed by tissue reperfusion, confers subsequent protection against the 
magnitude of tissue injury following ischaemia. This concept was introduced 30 years ago in 
a study which demonstrated that cycles of ischaemia and reperfusion of coronary arteries are 
able to protect the myocardium from subsequent prolonged ischaemia and reperfusion, 
leading to a reduction in infarct size (Murry et al., 1986). A follow-up study, by Przyklenk 
and co-workers (Przyklenk et al., 1993), demonstrated that cycles of coronary ischaemia and 
reperfusion also protect remote cardiac tissue not directly exposed to the ischaemia-
reperfusion cycles. This study stimulated substantial research that resulted in the clinical 
application of IPC of a limb to protect remote tissue and/or organs, such as the heart, against 
the magnitude of tissue loss consequent to an ischaemic event (Pickard et al., 2015). 
Reduction of myocardial damage by remote IPC, including improvement in clinical 
outcomes, has been demonstrated when applied in patients prior to cardiac surgery 
(Thielmann et al., 2013) and in patients with suspected myocardial infarction treated with 
IPC in the ambulance (Botker et al., 2010). Subsequently, studies have explored the impact of 
increasing the ‘dose’ of the traditional IPC-protocol (i.e. 3-4 cycles of 5-minutes ischaemia 
interspaced with 5 mins of reperfusion). Given the potent effects of a single dose of IPC, 
repeated episodes of IPC may, in theory, provide longer or more potent reduction in 
ischaemic myocardial damage (Whittaker & Przyklenk, 2014).  
 
A second potential benefit of IPC has emerged from studies that have explored the effects of 
repeated IPC (i.e. daily episodes of the 4 bouts of ischemia and reperfusion) on systemic 
vascular function and health. Improvement in vascular function as a consequence of repeated 
IPC may contribute to a reduction in the risk of developing ischaemic events. Hence, IPC 
may be of direct benefit in terms of reducing the impact of infarction on affected cardiac 
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muscle, but also reducing the likelihood of atherothrombotic events occurring in the first 
instance by virtue of this impact on endothelial and vascular function.  
 
The purpose of this review is to summarise research work that has investigated the potential 
impact of repeated (remote) IPC on both the ability to reduce ischaemic (myocardial) 
damage, and the capacity to improve vascular function. We also summarise proposed 
underlying mechanisms contributing to these adaptations of repeated (remote) IPC.  
 
1. Application of IPC in (pre)clinical work  
1.1 Historical overview IPC 
Murry et al. introduced the potential cardioprotective benefits of an episode of IPC (Murry et 
al., 1986). In this study, the IPC protocol involved occlusion of left anterior descending artery 
of dogs 4 times (for 5-minutes per occlusion), alternated with 5-minutes of reperfusion. This 
was followed by 40-minute ischaemia of the same artery. A 75% smaller infarction size was 
evident after IPC, compared to control animals that underwent a sham-intervention. This 
finding provided experimental support for clinical observations in the mid-1980s, which 
suggested that post-myocardial infarction patients with a prior history of angina (i.e. 
myocardial ischaemia) demonstrated better ejection fraction (Matsuda et al., 1984). These 
data contributed to the concept that exposure to (non-lethal) cardiac ischaemia in the period 
preceding coronary ischaemia may protect against the impact of reperfusion of the occluded 
artery on the magnitude of myocardial damage. Subsequent studies provided further clinical 
evidence that “pre-conditioning” of the myocardium before an acute myocardial infarction, 
for example through prodromal angina, leads to a smaller infarct size (Ottani et al., 1995) and 
improves (in-hospital) outcome (Kloner et al., 1995; Nakagawa et al., 1995). 
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Despite these intriguing observations, direct clinical application of IPC is challenging and 
associated with some limitations. Compared to control groups undergoing traditional CABG, 
smaller post-surgery release of cardiac troponins was observed after IPC applied to human 
coronary arteries preceding coronary artery bypass surgery (CABG) (Jenkins et al., 1997), 
along with attenuated impairment in cardiac function (Wu et al., 2000). Nevertheless, the 
direct application of IPC to coronary vessels can only be applied to planned ischaemic injury 
or surgery and is obviously impractical in humans.  
 
1.2 Effect remote IPC  
Przyklenk and colleagues performed a landmark study in 1993, in which they demonstrated 
that cyclical ischaemia and reperfusion of the circumflex coronary artery was associated with 
protection of cardiac territory supplied by the left anterior descending artery (i.e. an area 
remote from the distribution of the circumflex coronary artery) (Przyklenk et al., 1993). They 
provided support for the notion that IPC can afford infarct-sparing protection for distinct 
areas within the heart; and initiated several investigations to explore the potential effects of 
remote IPC (RIPC). Preclinical studies exploring the effects of RIPC have typically collected 
perfusate from ischaemic preconditioned tissue/animals and subsequently perfused naïve 
hearts using a Langendorff preparation. Interestingly, several studies have demonstrated that 
infarct sizes were significantly smaller in both donor hearts subjected to IPC and the naïve 
recipient hearts that received the perfusate from a pre-conditioned donor (Dickson et al., 
1999; Huffman et al., 2008) (Figure 1). This demonstrates the ability of IPC to reduce 
damage upon ischaemic injury in remote areas, possibly through a blood-borne pathway. 
Furthermore, evidence is present for between-species protection of RIPC, since rabbit hearts 
demonstrated protection against prolonged ischaemia when perfused with human 
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preconditioned serum (Shimizu et al., 2009; Michelsen et al., 2012). This suggests a 
similarity in the factor/s conferring protection across species, and that such agent/s remain 
conserved during such procedures, allowing binding to the recipient receptors. 
 
Experimental observations on the impact of RIPC have been supported by clinical studies 
demonstrating the potential of RIPC to prevent or attenuate (ischaemia-induced) tissue 
damage in the heart and various other organs (e.g. liver, brain, vascular endothelium and 
skeletal muscle (Pang et al., 1995; Yoshizumi et al., 1998; Stenzel-Poore et al., 2003; Jabs et 
al., 2010)). Kharbanda et al. used a swine model of RIPC of the limb (using a blood pressure 
cuff) and evoked reduction in the magnitude of myocardial damage against prolonged 
ischaemia (Kharbanda et al., 2002). Kharbanda et al. extended their findings by examining 
endothelial ischaemia-reperfusion injury in humans and demonstrated that RIPC induced by 
forearm ischaemia protected the contra-lateral forearm against endothelial ischaemia-
reperfusion injury. Other studies in humans followed-up on these findings and introduced 
RIPC (using a blood pressure cuff around a limb) as a simple strategy to evoke protective 
effects against subsequent ischaemia in remote territories. 
 
Studies have typically explored clinical effects by applying an episode of cyclical RIPC on a 
limb, before (planned) prolonged myocardial ischaemia. Several studies have examined the 
impact of RIPC in patients undergoing impending CABG or percutaneous coronary 
interventions (PCI), as these strategies induce global myocardial ischaemia (and subsequently 
cardiac damage) as reflected by a post-surgery elevation in cardiac troponins. Accordingly, 
strategies that can attenuate the global myocardial ischaemia have clinical relevance. Most of 
these studies reported lower peri-/post-operative levels of troponins in patients undergoing 
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CABG and elective PCI (Heusch, 2013), findings reflected by meta-analyses (Brevoord et al., 
2012; D'Ascenzo et al., 2012). More importantly, RIPC may reduce peri-operative 
myocardial infarction (Brevoord et al., 2012; Thielmann et al., 2013) as well as post-
operative atrial fibrillation (Candilio et al., 2015). For example, Thielmann and co-workers 
demonstrated in 329 patients undergoing CABG that preceding RIPC reduced post-CABG 
troponin levels, and also lowered all-cause mortality following 1.5-years follow-up 
(Thielmann et al., 2013). RIPC may possess potential long-term clinical benefit in humans. 
 
Instituting RIPC before prolonged ischaemia does not seem to be a pre-requisite for 
cardioprotection, since RIPC, applied to the lower limbs of pigs during cardiac ischaemia, 
was also associated with reduced severity of myocardial infarction and improved indices of 
cardiac function (Schmidt et al., 2007). In 2010, Bøtker and colleagues explored this concept 
in humans by randomising patients with suspected acute myocardial infarction to RIPC or a 
control intervention during transport to the hospital for primary PCI (Botker et al., 2010). 
They found that RIPC before hospital admission was associated with better myocardial 
salvage, measured by myocardial perfusion imaging. A follow-up study of this patient 
population indicated that, after a median follow-up of 3.8 years, the RIPC-treated patients 
experienced fewer major adverse cardiac and cerebrovascular events (Sloth et al., 2014) 
(Figure 2). The potential of RIPC to improve outcomes in patients with acute myocardial 
infarction undergoing primary PCI was supported by subsequent studies (Munk et al., 2010; 
Rentoukas et al., 2010). 
 
1.3 Potential problems with IPC 
A consensus has emerged that RIPC confers beneficial cardioprotective effects, reduces 
myocardial damage and confers fewer cardiovascular events post-surgery/event. These 
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effects seem largely independent of species, timing of RIPC, and/or the protocol of RIPC. 
Nevertheless, a number of potential concerns have been raised pertaining to this body of data. 
The majority of pre-clinical work is based on healthy animals, whilst ischaemic heart disease 
in humans is a complex disorder that may interfere with the efficacy of RIPC (Ferdinandy et 
al., 2007). The ageing process (Boengler et al., 2009) or anaesthetics/drug intake (Ferdinandy 
et al., 2014) may also interact with pathways normally associated with beneficial IPC effects. 
 
Tissue damage is mediated by prolonged ischaemia per se, but also through reperfusion of 
the ischaemic tissue, commonly referred to as ischaemia-reperfusion injury. Endothelial cells 
are particularly sensitive to ischaemia-reperfusion injury, leading to endothelial injury and 
swelling. Damage to the endothelium can contribute to further ischaemia by impeding blood 
flow upon reperfusion, which has been termed the ‘no-reflow phenomenon’ and is present in 
the myocardium (Chan et al., 2012) as well as the brain (Asiedu-Gyekye & Vaktorovich, 
2003). Impaired endothelial function is therefore clinically relevant, since the no-reflow 
phenomenon may lead to larger tissue damage and is associated with worse clinical outcome 
and increased mortality in patients undergoing PCI (Chan et al., 2012). Studies in humans 
often utilise brachial artery endothelial function (e.g. using flow-mediated dilation) as a valid 
surrogate for coronary function, before and after upper limb ischaemia, followed by 
reperfusion. In a series of recent studies, we explored the impact of older age and heart failure 
on the efficacy of IPC in humans to prevent endothelial ischaemia-reperfusion (van den 
Munckhof et al., 2013; Seeger et al., 2014a). We found that IPC prevented the decline in 
endothelial function after ischaemia-reperfusion in young healthy, but not older individuals 
(van den Munckhof et al., 2013). In line with these observations, heart failure patients 
demonstrated reduced efficacy of IPC to prevent endothelial ischaemia-reperfusion injury 
(Seeger et al., 2014a). The latter study also revealed that heart failure patients demonstrate an 
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exaggerated decline in endothelial function after ischaemia-reperfusion injury, compared to 
age-matched healthy controls.  
 
The data outlined in this sub-section support the concept that cardiovascular comorbidities 
and/or aging may modify endothelial ischaemia/reperfusion and, consequently, alter the 
infarct-sparing effects conferred by IPC. Although older age is associated with 
(cardiovascular) co-morbidities, it seems unlikely that the age-related loss in preconditioning 
can be solely explained by the presence of such co-morbidities (Boengler et al., 2009) since 
some studies report attenuated efficacy of IPC in older individuals free from co-morbidities 
and/or cardiovascular (CV) risk factors (van den Munckhof et al., 2013). Furthermore, animal 
work has linked age-related changes in Connexin 43 to a heart less resilient to the prevailing 
preconditioning stimulus (Boengler et al., 2007). Finally, it is important to emphasise that the 
age-related loss of preconditioning efficacy is likely reversible, given the ability of diet 
and/or exercise training to (partly) restore the reduction in IPC effect (Abete et al., 2010; 
Devan et al., 2011). 
 
2. What are the cardiovascular adaptations to repeated IPC? 
2.1 Repeated IPC and myocardium 
Only a few studies on repeated IPC have directly focused on the myocardium and the ability 
of episodic IPCs to impact the magnitude of myocardial damage. For example, 40 patients 
with coronary artery disease who were scheduled for coronary artery bypass graft (CABG) 
surgery were randomised to a 20-day period of repeated RIPC (3 IPC sessions daily, n=20) or 
a control intervention prior to surgery (n=20) (Liang et al., 2015). Patients undergoing 
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repeated RIPC demonstrated ~50% lower troponin expression levels after CABG compared 
to the control group. The ability of repeated RIPC to reduce post-surgery cardiac troponin is 
in line with previous work on single RIPC scheduled prior to CABG (see section 1.2).  
 
Currently there are clinical trials underway in the UK (NCT01664611) and Canada 
(NCT01817114) examining the impact of 28-days of daily repeated RIPC in patient’s post- 
myocardial infarction. Both trials are applying RIPC on the limb and exploring the impact 
upon left ventricular ejection fraction (LVEF), measured using cardiac magnetic resonance 
imaging. These trials represent a logical follow-up on some recent studies performed in 
animals. One of these studies explored different protocols of RIPC in rats undergoing planned 
cardiac ischaemia, including a single episode of RIPC and repeated (every 3 days versus 
daily) RIPC across 28 days post-injury (Wei et al., 2011). Although reduction in infarct size 
at day 4 and 28 was comparable across the protocols, repeated RIPC was associated with a 
dose-dependent protection against adverse remodelling and improved survival. In parallel 
with these findings, a recent study from Yamaguchi et al. (2015) divided post-myocardial 
infarction rats into a 4-week repeated RIPC-group and control-group and reported that 
repeated RIPC prevents adverse cardiac remodelling (and fibrosis in the boundary region). 
Yamaguchi and co-workers further explored the potential underlying mechanisms by 
examining expression of miR-29a (anti-fibrotic effects) and insulin-like growth factor 1 
receptor (IGF-1R; prevents progression of cardiac remodelling) in the myocardium and 
serum exosomes (Yamaguchi et al., 2015). Interestingly, repeated RIPC restored the down-
regulation of miR-29a in the infarcted myocardium, and increased miR-29a expression in 
serum exosomes. The lower fibrosis after RIPC may therefore occur through exosome-
mediated transmission of miR29-a, with subsequent endocytosis of miR-29a in the heart. 
Similarly, expression of IGF-1R was markedly increased in the hind limb (exposed to 
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repeated RIPC), serum exosomes and the myocardium, further supporting the observation 
that repeated RIPC may initiate exosome-mediated intercellular communication. Therefore, 
animal data exploring the effects of repeated RIPC suggest a potential impact of this novel 
intervention to improve clinical outcomes post-myocardial infarction. 
 
One previous study examined the magnitude of infarct size after 60-minutes of coronary 
artery occlusion in pigs that either underwent a preceding sham intervention, traditional IPC 
or repeated episodes of coronary ischaemia and reperfusion (6 cycles of 90-min occlusion, 
followed by 12-h reperfusion) (Shen et al., 2008). Whilst the sham-intervention resulted in an 
infarct size of 42% from the area at risk, traditional IPC and repeated IPC significantly 
reduced the infarct size relative to the area at risk to 16% and 6%, respectively. These data 
demonstrate that repeated IPC protocol conferred cardioprotection against lethal myocardial 
ischaemia that may exceed the benefits of a single IPC. Interestingly, microarray gene 
expression level analysis was used to understand the underlying mechanisms, and highlight 
that the mechanisms for protective effects of single day and repeated IPC may differ given 
the marked differences in gene expression levels (Shen et al., 2008; Depre et al., 2010). 
Future studies are required to better understand the potential benefits of repeatedly 
performing IPC cycles versus single IPC to confer the infarct-sparing effects. 
 
2.2 Repeated IPC and vasculature: healthy individuals 
In addition to the potential effects of repeated RIPC on reducing the magnitude of cardiac 
damage following infarction and prolonged ischaemia, repeated RIPC may demonstrate a 
generalised effect on endothelial function. These potential effects of repeated RIPC on 
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vascular function are of particular importance, since previous studies have demonstrated that 
improvement in peripheral and coronary vascular function is related to lower risk for future 
cardiovascular events (Schachinger et al., 2000; Green et al., 2011).  
 
Kimura and colleagues were the first to examine the effects of repeated RIPC following 28 
days of IPC on forearm resistance artery endothelial function in healthy individuals (Kimura 
et al., 2007) (Figure 3). They provided evidence that repeated RIPC enhanced resistance 
artery endothelial function via increases in nitric oxide (NO) production, whilst daily 
repeated RIPC augmented both circulating endothelial progenitor cells (EPCs) and plasma 
levels of vascular endothelial growth factors (VEGF). Luca et al. (2013) followed this work 
by exploring whether repeated (daily) IPC alters the efficacy of a single IPC against 
endothelial ischaemia reperfusion injury. They also found that 7-days of daily IPC provided 
sustained protection against ischaemia reperfusion injury of the endothelium of peripheral 
arteries (Luca et al., 2013). More recently, we extended these findings of enhanced vascular 
endothelial function and found that 7-days of daily IPC improved FMD as well as perfusion 
to the skin (e.g. enhanced microvascular function) in the ipsi- (i.e. localized to arm receiving 
the IPC-stimulus) and contralateral arms (i.e. remote from arm receiving the RIPC-stimulus). 
Effects of repeated IPC persisted for 7-days following the cessation of the intervention (Jones 
et al., 2014) (Figure 4). In addition to these effects on the vasculature, previous work 
suggests anti-inflammatory effects of repeated RIPC, since 10-day daily RIPC reduced 
neutrophil adhesion (Shimizu et al., 2010).  
 
It has been suggested that infarct-sparing effects from IPC are present for 1-2 h following an 
IPC episode (early phase), whilst these protective effects return after 24 h for a period of 3-4 
days (late phase). Although described in relation to protection of the ischaemic myocardium, 
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this pattern may also affect peripheral vessels. Therefore, repeated IPC bouts may be timed 
24-72 h apart to ensure that tissue will be exposed to the ‘early’ and ‘late’ phase of 
protection, at the same time. Combining these effects may be of clinical relevance, since the 
‘early’ and ‘late’ phases may have distinct protective mechanisms (Bolli, 2000). Given the 
relatively long duration of the ‘late’ phase of protection, we explored whether less frequent 
(and arguably more practical) exposure to repeated IPC is sufficient to induce vascular 
adaptation (Jones et al., 2015). We found that 8-weeks of IPC (3 cycles per week) 
significantly improved brachial artery endothelial function, and that this effect was evident 
after 2-weeks (i.e. 6 sessions of IPC) of the 8-week intervention. Presence of (sustained and 
systemic) improvement in peripheral endothelial function may be clinically relevant, 
particularly given the agreement with coronary endothelial function (Takase et al., 1998; 
Takase et al., 2005) and its prognostic value for future CV events (Green et al., 2011; Ras et 
al., 2013). Given the clinical benefits of adaptations in coronary arteries for cardioprotection, 
future studies are recommended to further explore these effects of repeated IPC. 
 
2.3 Repeated IPC and vasculature: cardiovascular disease  
Studies using repeated IPC interventions have also revealed positive effects on vascular 
function in those with pre-existing cardiovascular disease. For example, improved brachial 
artery FMD was observed in patients with coronary artery disease who were scheduled for 
coronary artery bypass graft (CABG) surgery and underwent a 20-day period of repeated 
RIPC (3 IPC sessions daily) (Liang et al., 2015). Moreover, vascular tissue harvested during 
CABG surgery demonstrated that patients who underwent repeated RIPC had increased 
expression of both eNOS mRNA and STAT-3, and also found increased levels of endothelial 
progenitor cells (Liang et al., 2015). These findings may provide a mechanistic explanation 
for improvement in vascular function after repeated RIPC. Whilst the majority of papers 
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focused on peripheral vascular effects, Kono and co-workers explored the effects of 7-days of 
bilateral RIPC on coronary flow reserve in patients with congestive heart failure and healthy 
individuals (Kono et al., 2014). The findings of that study demonstrate significant 
improvement in coronary flow reserve after repeated RIPC. These observations are of clinical 
relevance, since improvements in coronary flow reserve are linked to reduction in 
cardiovascular risk. 
 
2.4 Impact of repeated IPC: clinical outcomes  
The ability of repeated RIPC to alter vascular and cardiac function, and also impact cardiac 
remodelling, raises questions about its impact on clinical endpoints. Meng and colleagues 
were the first to perform a repeated RIPC intervention in a clinical setting, assessing the 
effects of 300-days of twice daily RIPC on stroke recurrence and cerebral perfusion in 
patients with intracranial arterial stenosis (Meng et al., 2012). Lower stroke recurrence was 
found in the IPC group at 90 and 300 days (5.0 and 7.8%, respectively) compared to the 
control group (23.3 and 26.7%, respectively). Patients receiving the repeated RIPC-protocol 
also demonstrated a significantly shorter time to recovery and improved cerebral perfusion. 
Improvement in event-free survival in the group that received repeated RIPC was recently 
reinforced by another study from the same group. In this study, significant protection against 
stroke recurrence was observed after 180-days of twice daily RIPC in symptomatic 
intracranial arterial stenosis patients (Meng et al., 2015). 
 
Another recent study examined the impact of repeated RIPC on diabetic wound healing in 
diabetes mellitus type 1 and 2 patients (Shaked et al., 2015). Patients with foot ulcers were 
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randomised to 6-week bilateral repeated RIPC (upper limbs) or a control intervention. The 
ratio of patients who reached complete healing of their ulcer was significantly better in those 
who received repeated RIPC compared to the control group (41% vs 0%), whilst the 
remaining ulcer area was smaller (25% vs 61%, respectively). A higher prevalence of 
complete healing is clinically relevant since 20% of patients with diabetic foot ulcers 
ultimately require amputation (Eldor et al., 2004). Taken together, these data suggest a 
potential clinical relevance of repeated RIPC in patient groups. Nevertheless, randomised 
controlled trials are required to further understand the clinical relevance of repeated RIPC in 
patient groups. 
 
3. IPC: Potential mechanisms 
Studies exploring the mechanisms for cardioprotection from repeated IPC are currently 
lacking. In the following sections, we have distinguished between the distinct local and 
remote effects of IPC versus RIPC, respectively. Within these sections, we have described the 
mechanisms which mediate the beneficial effects of a single episode of IPC or RIPC to 
mediate the infarct-sparing effects. Repeated activation of these effects may represent the 
first explanation for the benefits of repeated IPC. Nevertheless, it is important to 
acknowledge that mechanisms that contribute to the cardioprotection achieved through single 
episodes of IPC do not necessarily relate to the observations after repeated exposure to IPC 
(Shen et al., 2008; Depre et al., 2010). 
A second explanation for the benefits of repeated IPC is the activation of pathways and/or 
stimuli that contribute to improvement in vascular structure and function. To understand 
these adaptations, it is important to acknowledge that repeated IPC induces local and remote 
improvements in (cardio)vascular function (Table 1). Adaptations in local areas may be the 
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result of changes in haemodynamics induced by the IPC stimulus and/or by activation of 
pathways involved in the protective effects of IPC. In addition, alternative stimuli, such as 
blood-borne factors, must be present to mediate (cardio)vascular adaptation in remote areas. 
 
3.1 Local effects IPC: infarct-sparing effects 
As a consequence of IPC, signalling molecules are released that activates a mediator to 
transmit the cardioprotective signal that attenuates ischaemic injury. Consistent evidence 
supports the involvement of adenosine, bradykinin, and opioids (Liu et al., 1991; Schulz et 
al., 1998; Hu et al., 2007; Shimizu et al., 2009), which are released by cells directly exposed 
to IPC. Other signalling molecules have been identified, such as NO, hydrogen sulfide and 
reactive oxygen species (Heusch, 2015). The importance of these signalling molecules has 
typically been demonstrated by exploring myocardial infarct size after prolonged ischaemia 
of an animal heart after IPC during specific pharmacological blockade, or infusion of 
agonists.  
Expression of signalling molecules leads to activation of mediators that transmit the 
protective signal in the cytosol. An important mediator contributing to cardioprotective 
effects of IPC is protein kinase C (Liu et al., 1994). Others suggest an important role for NO 
in protecting against ischaemic injury through cGMP formation and PKG activation 
(Oldenburg et al., 2004; Yang et al., 2013). Given the potent anti-atherogenic and vasodilator 
effects of this substance, the involvement of the NO-pathway is clinically relevant. 
Furthermore, IPC-mediated protection also occurs via the Reperfusion Injury Salvage 
Kinases (RISK)-pathway (involving activation of PI3K, Akt and ERK) and Survivor 
Activating Factor Enhancement (SAFE)-pathway (involving TNFα and STAT-3), whilst 
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evidence also supports a role for protein kinases, hypoxia-inducible factor 1α, and 
microRNA-144. 
 
Ultimately, most, if not all, of the signalling pathways converge at the mitochondria, the most 
important effector of protection induced by IPC. Periods of ischaemia have deleterious 
effects on the mitochondria, ultimately limiting the production of ATP and leading to cell 
necrosis. A crucial step in this process is the opening of the mitochondrial permeability 
transition pore (MPTP), a finding supported by preclinical evidence showing infarct sparing 
effects when infusing MPTP inhibitors (see review (Ong et al., 2015)). Also, ATP-dependent 
potassium channels (KATP), especially those on the inner mitochondrial membrane, contribute 
to the protective effects of IPC against prolonged ischaemia (Ardehali & O'Rourke, 2005). 
Whilst IPC has well-established local infarct-sparing effects on the myocardium, the 
mechanisms underlying the translation of IPC to remote tissues is somewhat unclear. 
 
3.2 Local effects IPC: vascular adaptation 
IPC has a characteristic temporal nature, involving an acute protection that disappears ~2 hr 
after the preconditioning stimulus, and a delayed window of protection that appears after ~24 
hr that lasts longer, but may be less protective (Marber et al., 1993; Heusch, 2015). Whilst 
the acute protection depends on immediate recruitment of signaling molecules, increased 
expression of protective proteins is a hallmark of delayed protection (Bolli et al., 2007). 
Whilst endogenous NO, generated from endothelial and inducible NOS, seem not a requisite 
for immediate protection, it is involved in the delayed protective effects of IPC (Bolli et al., 
1998; West et al., 2008). In support of this, infarct-sparing effects of the late phase of IPC are 
abolished by a nonselective NOS inhibitor and selective iNOS inhibitor (Takano et al., 1998). 
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Expression of other cardioprotective proteins is also upregulated during delayed protection 
(e.g. COX-2, superoxide dismutase and heme oxygenase) (Zhou et al., 1996; Guo et al., 
2000; Brooks et al., 2014). These effects on the upregulation of (cardioprotective) proteins 
may contribute to the sustainability of the IPC stimulus and vascular adaptation. Therefore, 
repetitive upregulation of these proteins, typically observed during the delayed protective 
phase, may be of relevance in understanding the effects of repeated IPC on sustainable 
improvement in vascular function. Whether these effects indeed translate to the peripheral 
vascular beds, also taking into consideration the presence of potential deleterious remodeling, 
is currently unknown. 
 
An alternative explanation for local adaptations in vascular function and structure induced by 
repeated IPC relates to the cyclical exposure to changes in local haemodynamics induced by 
the episodes of ischaemia and reperfusion, such as elevations in blood flow (or shear stress). 
Previous work has demonstrated that repeated increases in shear represent an important 
stimulus for vascular adaptations in function and structure (Green et al., 2004; Tinken et al., 
2010). The perception that vascular adaptations are mediated by shear stress dependent 
mechanisms is well supported by both in vivo animal models and human experiments 
(Hambrecht et al., 2003; McAllister et al., 2005; Green et al., 2010). In addition, repeated 
exposure to short periods of hypoxia (or ischaemia) may also contribute to cardiac and 
vascular adaptations (Laughlin et al., 2008; Newcomer et al., 2011). Given that repeated 
exposure to elevations in blood flow (or shear stress) and hypoxia are key characteristics of 
IPC in a limb exposed to the stimulus, any localised vascular adaptations in the limb directly 
exposed to IPC could be mediated by increased shear stress and also the hypoxic release of 
local metabolic byproducts.  
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3.3 Systemic effects of remote IPC: infarct-sparing effects 
In the classic view on the cardioprotective effects of RIPC, a trigger is released (i.e. in the 
occluded limb) and acts as the stimulus to activate a mediator, which transmits a protective 
signal onto an effector that attenuates injury in remote (cardiac and vascular) areas in 
response to ischaemia-reperfusion. Given the complexity of the activation of these pathways, 
involvement of many signals, and also how they confer subsequent protection, we refer to 
recent reviews that provide a comprehensive overview of these mechanisms (Heusch, 2015; 
Heusch et al., 2015). Below, we have provided a short, condensed overview of the most 
important pathways involved in the immediate infarct-sparing effects of RIPC. Although 
speculative, these pathways may contribute to the infarct-sparing effects of repeated IPC.  
 
The stimulus for RIPC relevant in the model of repeated IPC originates from the episodes of 
ischaemia and reperfusion applied to a limb. Subsequent transduction of the local signal to 
remote tissues is dependent on (intact) neural pathways and humoral pathways that are able to 
reach the remote target tissue or organ (Gho et al., 1996; Lim et al., 2010). For example, 
several studies have demonstrated the role of neural pathways in signal transduction in RIPC 
(including somatosensory system, the spinal cord and the autonomic system), by reporting 
abrogation of protection after pharmacologically or surgically affecting neural pathways (Gho 
et al., 1996; Loukogeorgakis et al., 2005; Jones et al., 2009). Similarly, cardioprotection of 
RIPC is also mediated through circulating, blood-borne hormones that are able to protect 
remote (cardio)vascular regions against prolonged ischaemia (Dickson et al., 1999), with 
recent evidence supporting a potential role for NO, microRNA-144 and stromal derived 
factor 1α. In the target organ, signal transduction pathways are activated that ultimately 
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contribute to the protection against ischaemic injury. In the heart, signal transduction of RIPC 
‘shares’ that of local IPC, with at least significant involvement of NO (and eNOS), PKC and 
the RISK-pathway that ultimately work on the mitochondria (Heusch et al., 2015).  
 
3.4 Systemic effects of remote IPC: vascular adaptation  
The production of circulating hormones represents one logical mechanism that might 
contribute to the effects of repeated IPC on both the ability to ameliorate damage after 
prolonged ischaemia and sustained adaptation in remote vascular function. The role of 
circulating hormones in the protection against myocardial injury was first highlighted by 
Dickson et al., who found that coronary effluent from a pre-conditioned heart induced 
cardioprotection in a naïve acceptor heart (Dickson et al., 1999) (Figure 1). Several 
subsequent studies, typically adopting the Langendorff bioassay, suggested the presence of a 
blood-borne substance that confers protection when infused in an organ exposed to prolonged 
ischaemia. Despite the scientific and clinical importance, identifying the substance, or 
substances, that explain the effects of RIPC has proven challenging. At least some part of the 
remote protection has been attributed to microRNA-144, stromal-derived factor-1α (SDF-1α) 
and NO (Pickard et al., 2015). Increased bioavailability of NO, via conversion from 
circulating nitrite, may reduce myocardial damage during prolonged ischaemia, whilst the 
effects of RIPC were diminished in animals deficient in endothelial NO synthase (Rassaf et 
al., 2014). Similarly, cardioprotection provided by RIPC was partially abolished using an 
inhibitor of SDF-1α (Davidson et al., 2013). Finally, recent work suggests that RIPC-induced 
release of microRNA-144 contributes to the cardioprotection, since the efficacy of RIPC is 
reduced when combined with an antagomir to microRNA-144 (Li et al., 2014). Whilst NO, 
SDF-1α and microRNA144 are capable, at least partly, of explaining some of the infarct-
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sparing effects of RIPC, these circulating hormones may also contribute to adaptations in 
peripheral and/or coronary arteries. 
 
As indicated earlier, due to the temporal differences in the effects of IPC (i.e. early versus 
late preconditioning), candidates contributing to the acute benefits of IPC may not necessarily 
contribute to more sustainable adaptations. For example, similar to IPC, RIPC is associated 
with sustainable decreases in iNOS (Wei et al., 2012). Furthermore, RIPC did not mediate 
acute mobilisation of endothelial progenitor cells, making it unlikely they contribute to the 
immediate protective effects, whilst increases in these cells were observed 12- and 24-hr after 
IPC (Kamota et al., 2009). This makes endothelial progenitor cells a potential candidate to 
contribute to improvement in vascular function in response to repeated IPC, especially given 
their ability to improve vascular function. Some support for this is provided by the 
observation of elevated levels of endothelial progenitor cells after 28-days of repeated IPC, 
which coincided with improvement in (peripheral) vascular function (Kimura et al., 2007).  
RIPC also represents a potent stimulus for inflammatory pathways. Despite its role in 
inflammation, upregulation of cytokine interleukin (IL)-6 is mandatory to mediate (remote) 
IPC (Zuurbier et al., 2012). The role for low levels of cytokines in the protection mediated by 
(remote) IPC is interesting, especially since excessive levels of cytokines are detrimental for 
ischaemic injury and vascular function. Such paradoxical observations can also be observed 
for TNFα and reactive oxygen species. Furthermore, expression of IL-10, a potent anti-
inflammatory cytokine, is upregulated during delayed protection of RIPC and late protection 
against ischaemia may be mediated by IL-10, since blockade of IL-10 receptors abolished 
cardioprotective effects whilst IL-10 infusion induced benefit (Cai et al., 2012). These data 
indicate that RIPC leads to sustainable changes in inflammatory pathways, possibly 
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contributing to prolonged protection against ischaemic injury and/or adaptation in vascular 
function/structure.  
 
Taken together, early and/or late effects of RIPC may contribute to infarct-sparing effects, 
but also to the generalized improvement in vascular function associated with repeated IPC, 
and therefore reduction in risk for CV events. The remote effects of IPC are an attractive 
explanation of the improvement in vascular function and/or structure, especially given 
sustained increases in circulating hormones during the late phase of RIPC that have direct 
relevance for vascular adaptation and health (e.g. NO, endothelial progenitor cells, IL-10). 
However, understanding the potential sustainable effects of repeated IPC is more complicated 
than simply exploring the early versus late effects of RIPC (Whittaker & Przyklenk, 2014). 
For example, previous work from Depre et al. found single and repeated RIPC to lead to 
comparable preconditioning effects, but with marked differences in gene expression (Depre et 
al., 2010). Furthermore, exposure to a large number of ischaemic episodes may cause local 
collagen damage, potentially leading to inflammation and fibrosis (Whittaker & Przyklenk, 
2014). Future work is required to explore the underlying mechanisms to understand the 
impact of repeated IPC. 
 
4. Summary, future directions and the potential clinical relevance of repeated IPC 
Previous work regarding IPC has largely focused on understanding the clinical benefits and 
mechanisms contributing to the effects of a single episode of IPC. Given the potency of these 
effects, more recent studies have explored the potential benefits associated with repeated 
IPC. Whilst this field is in its infancy, current evidence suggests that repeated IPC is 
associated with both local and remote adaptations in vascular function which likely relate to 
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lower risk for future CV events and protection against ischaemic injury. The ability to benefit 
from the protective effects of IPC against sustained myocardial ischaemic injury and/or to 
mediate improvements in vascular function makes repeated IPC a novel strategy that is 
feasible, low cost and easy applied. Some recent and provocative studies have linked repeated 
exposure to IPC to clinical cardio- and cerebro-vascular outcome benefits.  
 
Studies examining the mechanisms underlying the clinical effects of repeated IPC are scant. 
Current evidence suggest that both early (0-1 h) and late (24-72 h) effects are apparent in 
terms of attenuating and/or preventing ischaemic injury. Repeated IPC is also associated with 
both local (i.e. repeated increases in shear) and systemic mechanisms (i.e. circulating 
hormones, cytokines and growth factors) that contribute to improvement in vascular function 
and/or structure. By virtue of improved vascular function, lower risk for future CV events is 
possible. Future work is required to better understand the differences between the 
mechanisms underlying single and repeated IPC. The potential dual effects of repeated IPC 
on the prevention of events and attenuation of ischaemic injury makes this strategy 
potentially suitable in both primary and secondary preventive settings.  
 
The impact of repeated preconditioning has also assessed in relation to adaptations in 
exercise physiology (Thijssen et al., 2010). Interestingly, recent work in animals (Michelsen 
et al., 2012) and humans (Seeger et al., 2014b) has demonstrated the ability of exercise to 
protect against cardiac and endothelial ischaemia-reperfusion injury. Moreover, we 
demonstrated the ability of IPC to enhance exercise performance (de Groot et al., 2010), 
whilst others found effects of IPC in various types of exercise. IPC may be especially 
advantageous in exercise where hypoxia is a limiting factor (e.g. swimming) (Crisafulli et al., 
2011). Accordingly, it is tempting to postulate that exercise, either alone or in combination 
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with IPC, may serve as a preconditioning stimulus in clinical research and/or as a strategy to 
restore preconditioning in clinical populations.  
 
Taken together, increasing the ‘dose’ of a single IPC by repeated performance of this 
procedure represents an attractive, easy applicable and novel strategy. The ability to induce 
both local and systemic adaptations that may be associated with lower risk for future CV 
events, in addition to attenuation of the impact of ischaemic events, is highly attractive from a 
clinical viewpoint. Moreover, an increased ‘dose’ of IPC may overcome some of the issues 
associated with exposure to a single bout of IPC, such as attenuated efficacy in clinical 
groups. At the very least, this work deserves further exploration regarding the time course, 
sustainability and validity of potential benefits of repeated IPC in both healthy and clinical 
populations. Practical considerations such as the delivery of the stimulus, optimal dose and 
long-term safety remain to be addressed. 
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Table 1. Overview of published studies investigating impact of repeated IPC  
Author + Year Group Dose of IPC IPC/RIPC Uni-/Bilateral Control Duration Findings 
Kimura 2007 Healthy young  6x5 min daily RIPC Uni Control 4-weeks Vascular function (VOP-infusion) ↑ 
Endothelial progenitor cells ↑  
Shimizu 2010 Healthy middle-aged 3x5 min daily RIPC Uni None 10-days Neutrophil adhesion ↓ 
Phagocytosis ↓ 
Luca 2013 Healthy young  3x5 min daily RIPC Uni None 7-days Vascular function (FMD) ↑ 
Kono 2014 Healthy middle-aged 4x5 min 2/day RIPC Uni None 7-days Coronary flow reserve ↑ 
LV end-diastolic volume = 
Jones 2014a Healthy young 4x5 min daily IPC/RIPC Uni None 7-days Vascular function (FMD) ↑ (bilateral) 
Skin perfusion ↑ (bilateral) 
Jones 2015 Healthy young 4x5 min 3/week IPC/RIPC Uni Control 8-weeks Vascular function (FMD) ↑ (bilateral) 
Skin perfusion = 
Wei 2011 Rats – myocardial infarction 4x5 min daily RIPC Uni Sham 28-days Infarct size ↓ 
LV remodelling ↓ 
Meng 2012 Intracranial arterial stenosis  5x5 min daily RIPC Bi Control 300-days Stroke recurrence ↓ 
Brain perfusion ↑ 
Kono 2014 Heart failure 4x5 min 2/day 
 
RIPC Uni None 7-days Coronary flow reserve (CFR) ↑ 
LV end-diastolic volume = 
Liang 2015 Coronary heart disease 4x5 min 3/day RIPC 
 
 
Uni Control 20-days Vascular function (FMD) ↑ 
eNOS mRNA levels ↑ 
STAT-3 levels ↑ 
Endothelial progenitor cells ↑ 
Yamaguchi 2015 Rats – myocardial infarction  5x5 min daily RIPC Bi Control 4-weeks LVEF ↑ 
LV diastolic function ↑ 
Meng 2015 Intracranial arterial stenosis  5x5 min 2/day RIPC Bi Sham 180-days Stroke recurrence ↓ 
Shaked 2015 Type 1 & 2 diabetics  3x5 min 1/14 days RIPC Bi Sham 6-weeks Diabetic ulcer wound size ↓ 
FMD, flow mediated dilation; LVEF, Left Ventricular Ejection Fraction
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FIGURE LEGENDS 
 
FIGURE 1. Area of necrosis (AN) expressed as a percentage of total left ventricular (LV) 
weight (AN/LV) in rabbit hearts after a control (Control) or ischaemic 
preconditioning (PC) in the donor heart or in an acceptor heart (i.e. hearts that 
received effluent from donor). Derived from Dickson et al. (1999).  
 
FIGURE 2. Cumulative incidence (%, by year since randomisation, per-protocol analysis): 
(A) Major adverse cardiac and cerebrovascular events (MACCE) at P=0.010, 
(B) All-cause mortality at P=0.019, (C) Cardiac mortality at P=0.248, and (D) 
Non-cardiac mortality at P=0.045. Derived from Sloth et al. (2014).  
 
FIGURE 3. Impact of repeated IPC on the vasculature. (a) Brachial artery FMD (%) and (b) 
resting (baseline) forearm cutaneous vascular conductance (CVC) before (Pre), 
after (Post), and 8 days after (Post+8) the 7-day daily IPC intervention in the 
IPC (open circles) and contralateral arm (solid squares) of healthy volunteers 
(n=13). Error bars represent SE. *Post hoc significantly different from day 0. 
Derived from Jones et al. (Jones et al., 2014). 
 
FIGURE 4. Comparison of forearm blood flow (FBF) responses to incremental doses of 
acetylcholine (ACh) at 0 weeks and 4 weeks of follow-up in the control groups 
(A) and in the group that received daily unilateral ischaemic preconditioning 
with data presented for the untreated, contralateral arm (B) and treated, 
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preconditioned arm (C). Error bars represent SE. Derived from Kimura et al. 
(Kimura et al., 2007). 
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